Your AI-Trained Oncology Knowledge Connection!
The FDA’s ODAC voted in favor of the risk/benefit profile of subcutaneous daratumumab in high-risk smoldering multiple myeloma.
Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.
Michael K. Wong, MD, PhD, FRCPC, discusses the landscape of Merkel cell carcinoma, including the role of immunotherapy and multidisciplinary treatment.
Historic surgery, the result of years of research at Keck Medicine of USC and UCLA Health, opens the door for improved treatment of non-functioning bladders
Lymphodepletion was associated with enhanced MAR T-cell response and antitumor activity with MT-601 in patients with relapsed/refractory lymphoma.
The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.
The ACTIVATE trial confirmed the safety and enhanced efficacy of Acoustic Cluster Therapy plus chemotherapy in patients with metastatic colorectal cancer.
In the colorectal cancer space, the role of ctDNA can help reduce the use of certain therapies.
Cetuximab β was effective and safe in patients with RAS/BRAF wild-type metastatic colorectal cancer.
Experts highlight key abstracts and presentations to keep an eye on in gynecologic oncology at the 2025 ASCO Annual Meeting.
The B7-H3–directed CAR T-cell therapy BCB-276 received RMAT designation for the treatment of patients with diffuse intrinsic pontine glioma.
An exploratory ctDNA analysis from postMONARCH highlighted the benefit of abemaciclib plus fulvestrant across HR-positive breast cancer subgroups.
Matthew Galsky, MD, discusses the significance of the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in MIBC.
Collaborative Roswell Park/Columbia research uncovers greater risk of relapse and complications, lower survival rates.
The DLL3-targeted antibody-drug conjugate ZL-1310 has received FDA fast track designation for patients with extensive-stage small cell lung cancer.
Two belantamab mafodotin–based combinations have been approved in Japan for relapsed/refractory multiple myeloma.
During an OncLive Peer Exchange filmed during ASCO GU, expert investigators discussed significant updates in the RCC space.
Final analysis of SGNTUC-019 showed a 41.9% ORR, an 80.6% DCR, and a 18.2-month DOR with tucatinib/trastuzumab in pretreated, HER2-mutated metastatic breast cancer.
Oncology experts detail their most highly-anticipated hematology abstracts and data to watch at the upcoming 2025 ASCO Annual Meeting.
The top 5 OncLive videos of the week cover insights in ovarian cancer, prostate cancer, chronic lymphocytic leukemia, and breast cancer.
Alexis LeVee, MD, discusses treatment challenges associated with TNBC and ongoing trials that may improve outcomes for patients with early-stage disease.
The FDA has approved options in non–small cell lung cancer, advanced anal cancer, and pheochromocytoma or paraganglioma, and more from OncLive this week.
First-line cemiplimab extended median PFS and OS vs chemotherapy in patients with untreated advanced NSCLC with brain metastases.
T-DM1 plus palbociclib showed significant PFS in patients with HER2-positive metastatic breast cancer.
EL1SSAR data reinforce the importance of PD-L1 assessment to select patients with TNBC with the best outcomes on atezolizumab.
Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.
Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.
Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.
Frontline endocrine therapy plus entrectinib failed to decrease RCB to 0/1 in patients with invasive lobular breast carcinoma.
Press release
Historic donation unites two renowned institutions under one new world-class center created to end childhood cancer
